Standard

The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation. / Berger, Wouter R.; Jagu, Benoît; van den Berg, Nicoline W. E. et al.

In: Europace : European pacing, arrhythmias, and cardiac electrophysiology, Vol. 20, No. 5, 2018, p. 764–771.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Berger, WR, Jagu, B, van den Berg, NWE, Chan Pin Yin, DRPP, van Straalen, JP, de Boer, OJ, Driessen, AHG, Neefs, J, Krul, SPJ, van Boven, WP, van der Wal, AC & de Groot, JR 2018, 'The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation', Europace : European pacing, arrhythmias, and cardiac electrophysiology, vol. 20, no. 5, pp. 764–771. https://doi.org/10.1093/europace/eux090

APA

Berger, W. R., Jagu, B., van den Berg, N. W. E., Chan Pin Yin, D. R. P. P., van Straalen, J. P., de Boer, O. J., Driessen, A. H. G., Neefs, J., Krul, S. P. J., van Boven, W. P., van der Wal, A. C., & de Groot, J. R. (2018). The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation. Europace : European pacing, arrhythmias, and cardiac electrophysiology, 20(5), 764–771. https://doi.org/10.1093/europace/eux090

Vancouver

Berger WR, Jagu B, van den Berg NWE, Chan Pin Yin DRPP, van Straalen JP, de Boer OJ et al. The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation. Europace : European pacing, arrhythmias, and cardiac electrophysiology. 2018;20(5):764–771. Epub 2017. doi: 10.1093/europace/eux090

Author

Berger, Wouter R. ; Jagu, Benoît ; van den Berg, Nicoline W. E. et al. / The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation. In: Europace : European pacing, arrhythmias, and cardiac electrophysiology. 2018 ; Vol. 20, No. 5. pp. 764–771.

BibTeX

@article{370cba5b0d4442f0a956d7d5aee2f336,
title = "The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation",
abstract = "Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure. Increased Gal-3 concentration (Gal-3), associated with increased risk of developing atrial fibrillation (AF), may reflect atrial fibrotic remodelling underlying AF progression. We aimed to investigate whether the change in serum Gal-3 reflects alterations of the arrhythmogenic atrial substrate following thoracoscopic AF surgery, and predicts absence of AF. Consecutive patients undergoing thoracoscopic AF surgery were included. Left atrial appendages (LAAs) and serum were collected during surgery and serum again 6 months thereafter. Gal-3 was determined in tissue and serum. Interstitial collagen in the LAA was quantified using Picrosirius red staining. Ninety-eight patients (76% male, mean age 60 ± 9 years) underwent thoracoscopic surgery for advanced AF. Patients with increased Gal-3 after ablation compared to baseline had a higher recurrence rate compared to patients with decreased or unchanged Gal-3 (HR 2.91, P = 0.014). These patients more frequently had persistent AF, longer AF duration and thick atrial collagen strands (P = 0.049). At baseline, Gal-3 was similar between patients with and without AF recurrence: 14.8 ± 3.9 µg/L vs. 13.7 ± 3.7 µg/L, respectively in serum (P = 0.16); 94.5 ± 19.4 µg/L vs. 93.3 ± 30.8µg/L, respectively in atrial myocardium (P = 0.83). There was no correlation between serum Gal-3 and left atrial Gal-3 (P = 0.20), nor between serum Gal-3 and the percentage of fibrosis in LAA (P = 0.18). The change of circulating Gal-3, rather than its baseline value, predicts AF recurrence after thoracoscopic ablation. Patients in whom Gal-3 increases after ablation have a high recurrence rate reflecting ongoing profibrotic signalling, irrespective of arrhythmia continuation",
author = "Berger, {Wouter R.} and Beno{\^i}t Jagu and {van den Berg}, {Nicoline W. E.} and {Chan Pin Yin}, {Dean R. P. P.} and {van Straalen}, {Jan P.} and {de Boer}, {Onno J.} and Driessen, {Antoine H. G.} and Jolien Neefs and Krul, {S{\'e}bastien P. J.} and {van Boven}, {WimJan P.} and {van der Wal}, {Allard C.} and {de Groot}, {Joris R.}",
year = "2018",
doi = "10.1093/europace/eux090",
language = "English",
volume = "20",
pages = "764–771",
journal = "EP Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - The change in circulating galectin-3 predicts absence of atrial fibrillation after thoracoscopic surgical ablation

AU - Berger, Wouter R.

AU - Jagu, Benoît

AU - van den Berg, Nicoline W. E.

AU - Chan Pin Yin, Dean R. P. P.

AU - van Straalen, Jan P.

AU - de Boer, Onno J.

AU - Driessen, Antoine H. G.

AU - Neefs, Jolien

AU - Krul, Sébastien P. J.

AU - van Boven, WimJan P.

AU - van der Wal, Allard C.

AU - de Groot, Joris R.

PY - 2018

Y1 - 2018

N2 - Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure. Increased Gal-3 concentration (Gal-3), associated with increased risk of developing atrial fibrillation (AF), may reflect atrial fibrotic remodelling underlying AF progression. We aimed to investigate whether the change in serum Gal-3 reflects alterations of the arrhythmogenic atrial substrate following thoracoscopic AF surgery, and predicts absence of AF. Consecutive patients undergoing thoracoscopic AF surgery were included. Left atrial appendages (LAAs) and serum were collected during surgery and serum again 6 months thereafter. Gal-3 was determined in tissue and serum. Interstitial collagen in the LAA was quantified using Picrosirius red staining. Ninety-eight patients (76% male, mean age 60 ± 9 years) underwent thoracoscopic surgery for advanced AF. Patients with increased Gal-3 after ablation compared to baseline had a higher recurrence rate compared to patients with decreased or unchanged Gal-3 (HR 2.91, P = 0.014). These patients more frequently had persistent AF, longer AF duration and thick atrial collagen strands (P = 0.049). At baseline, Gal-3 was similar between patients with and without AF recurrence: 14.8 ± 3.9 µg/L vs. 13.7 ± 3.7 µg/L, respectively in serum (P = 0.16); 94.5 ± 19.4 µg/L vs. 93.3 ± 30.8µg/L, respectively in atrial myocardium (P = 0.83). There was no correlation between serum Gal-3 and left atrial Gal-3 (P = 0.20), nor between serum Gal-3 and the percentage of fibrosis in LAA (P = 0.18). The change of circulating Gal-3, rather than its baseline value, predicts AF recurrence after thoracoscopic ablation. Patients in whom Gal-3 increases after ablation have a high recurrence rate reflecting ongoing profibrotic signalling, irrespective of arrhythmia continuation

AB - Galectin-3 (Gal-3) is an important mediator of cardiac fibrosis, particularly in heart failure. Increased Gal-3 concentration (Gal-3), associated with increased risk of developing atrial fibrillation (AF), may reflect atrial fibrotic remodelling underlying AF progression. We aimed to investigate whether the change in serum Gal-3 reflects alterations of the arrhythmogenic atrial substrate following thoracoscopic AF surgery, and predicts absence of AF. Consecutive patients undergoing thoracoscopic AF surgery were included. Left atrial appendages (LAAs) and serum were collected during surgery and serum again 6 months thereafter. Gal-3 was determined in tissue and serum. Interstitial collagen in the LAA was quantified using Picrosirius red staining. Ninety-eight patients (76% male, mean age 60 ± 9 years) underwent thoracoscopic surgery for advanced AF. Patients with increased Gal-3 after ablation compared to baseline had a higher recurrence rate compared to patients with decreased or unchanged Gal-3 (HR 2.91, P = 0.014). These patients more frequently had persistent AF, longer AF duration and thick atrial collagen strands (P = 0.049). At baseline, Gal-3 was similar between patients with and without AF recurrence: 14.8 ± 3.9 µg/L vs. 13.7 ± 3.7 µg/L, respectively in serum (P = 0.16); 94.5 ± 19.4 µg/L vs. 93.3 ± 30.8µg/L, respectively in atrial myocardium (P = 0.83). There was no correlation between serum Gal-3 and left atrial Gal-3 (P = 0.20), nor between serum Gal-3 and the percentage of fibrosis in LAA (P = 0.18). The change of circulating Gal-3, rather than its baseline value, predicts AF recurrence after thoracoscopic ablation. Patients in whom Gal-3 increases after ablation have a high recurrence rate reflecting ongoing profibrotic signalling, irrespective of arrhythmia continuation

U2 - 10.1093/europace/eux090

DO - 10.1093/europace/eux090

M3 - Article

C2 - 28525549

VL - 20

SP - 764

EP - 771

JO - EP Europace

JF - EP Europace

SN - 1099-5129

IS - 5

ER -

ID: 3852629